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Abstract
Behavioural variant frontotemporal dementia (bvFTD) and Alzheimer’s disease (AD) dementia are characterised by
progressive brain atrophy. Longitudinal MRI volumetry may help to characterise ongoing structural degeneration and
support the differential diagnosis of dementia subtypes. Automated, observer-independent atlas-based MRI volumetry was
applied to analyse 102 MRI data sets from 15 bvFTD, 14 AD, and 10 healthy elderly control participants with consecutive
scans over at least 12 months. Anatomically defined targets were chosen a priori as brain structures of interest. Groups were
compared regarding volumes at clinic presentation and annual change rates. Baseline volumes, especially of grey matter
compartments, were significantly reduced in bvFTD and AD patients. Grey matter volumes of the caudate and the gyrus
rectus were significantly smaller in bvFTD than AD. The bvFTD group could be separated from AD on the basis of caudate
volume with high accuracy (79% cases correct). Annual volume decline was markedly larger in bvFTD and AD than controls,
predominantly in white matter of temporal structures. Decline in grey matter volume of the lateral orbitofrontal gyrus
separated bvFTD from AD and controls. Automated longitudinal MRI volumetry discriminates bvFTD from AD. In particular,
greater reduction of orbitofrontal grey matter and temporal white matter structures after 12 months is indicative of bvFTD.
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Introduction
Behavioural variant frontotemporal dementia (bvFTD) and
Alzheimer’s disease (AD) are the two most prevalent early-onset
dementias [1]. Diagnostic criteria for both have been proposed
[2,3] but clinical diagnosis remains challenging [4,5].
The revised diagnostic criteria for bvFTD [6] incorporate
neuroimaging evidence of frontal and/or temporal brain atrophy
changes at presentation. AD patients also show atrophy compared
to healthy controls particularly in the medial temporal lobe [7], as
well as precuneus [8] at presentation. By contrast, bvFTD show
characteristic frontal and anterior temporal lobe atrophy [9–11],
with the hippocampus being affected to a similar degree as in AD
[12–14]. Similarly, bvFTD and AD show differential white matter
changes involving frontal and parietal structures, respectively,
while both groups appear to show similar levels of temporal lobe
white matter change [12–14].
Despite the identification of typical atrophy patterns in at clinic
presentation in bvFTD and AD, longitudinal grey and white
matter changes have not been reported yet might be particularly
relevant for aiding diagnosis and for measuring disease progression
in context of potential disease modifying therapies.
The current study set out to investigate these longitudinal
changes in bvFTD and AD, compared to age-matched controls via
a novel automated, observer-independent method of atlas-based
MRI volumetry. This technique allows establishing volumetrics
both at cross-sectional and longitudinal levels. We hypothesised
that bvFTD and AD will show cross-sectionally the previously
described patterns of atrophy, while the longitudinal changes
would reveal additional regions affected in both diseases.
Methods
Ethics statement
The study was conducted in compliance with the Declaration of
Helsinki (1991). Data collection for this study had been approved
by the local ethics committees (University Medical Center,
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Freiburg; South Eastern Sydney and Illawarra Area Health
Service and the University of New South Wales).
Case selection
Thirty-nine participants were selected from the FRONTIER
database, Sydney, Australia and from a project database (German
Federal Ministry of Education and Research project ‘Mechanisms
of brain reorganisation in the language network’, BMBF:
01GW0662) in Freiburg, Germany. Data from 10 bvFTD and
14 AD patients, as well as 10 controls have been acquired in
Sydney. The study sample was complemented by 5 bvFTD
patients from Freiburg. Participants in the control group had been
chosen to be not significantly different from patient groups in
terms of age and education. In total, 102 MRI data sets from these
participants were analysed. All bvFTD patients met current
consensus criteria for FTD [6,15] with insidious onset, decline in
social behaviour and personal conduct, emotional blunting and
loss of insight. Of the 10 bvFTD patients from the FRONTIER
database, 3 had the C9ORF72 genetic mutation. All AD patients
met NINCDS-ADRDA diagnostic criteria [16] for probable AD,
with episodic memory deficits being the predominant symptoms
(see Table 1 for demographic details). Age- and education-
matched healthy controls were selected from a healthy volunteer
panel or were spouses/carers of patients. All patients gave written
informed consent.
All participants from the FRONTIER database underwent
general cognitive screening using the Addenbrooke’s Cognitive
Examination (ACE-R) [17] to determine their overall cognitive
functioning. The ACE-R results in a score out of 100, and includes
subsections in attention, memory, language and visuo-perception.
The frontotemporal dementia rating scale (FRS) [18] was used to
determine the disease severity in bvFTD and AD patients. The
Cambridge Behavioural Inventory (CBI) was used as a behav-
ioural disturbance measure with higher scores indicating more
behavioural disturbance as reported by the family or carer.
Participants from the Freiburg database were assessed using the
MMSE and the Clinical Dementia Rating.
MRI acquisition
All patient and controls from the FRONTIER database
underwent the same imaging protocol with whole-brain T1-
weighted images using a 3T Philips MRI scanner with standard
quadrature head coil (8 channels). The 3D T1-weighted sequences
were acquired as follows: coronal orientation, 161 mm2 in-plane
resolution, slice thickness 1 mm, TR/TE = 5.8/2.6 ms.
Structural T1-weighted MRI data from the Freiburg participants
were acquired on a 3T Siemens TIM-Trio scanner equipped with
a 12-channel headcoil using a 3D-MPRAGE sequence in sagittal
orientation with 161 mm2 in-plane resolution, slice thickness
1 mm, and TR/TE=2200/2.15 ms. The scanning protocols of
the two sites were held constant across subjects and over time. All
patients were scanned annually after a baseline scan. Controls had
a baseline scan as well as a follow-up scan after two years. Median
number of scans per subject was 2 (Mean = 2.6, S.D. = 0.7,
range 2 to 4 scans), the mean delay between the first and last scan
was 23.3 months (S.D. = 7.7, range 12 to 36.7 months).
MRI data processing and volumetric analysis
The MRI data processing and volumetry have been described
in detail elsewhere [19,20]. The method is based on SPM5
(statistical parametric mapping software, Wellcome Trust Centre
for Neuroimaging, London, UK; http://www.fil.ion.ucl.ac.uk/
spm), and masks derived from a probabilistic brain atlas provided
by the Laboratory of Neuroimaging (LONI) at the University of
California, Los Angeles, CA (LONI Probabilistic Brain Atlas
(LPBA40); http://www.loni.ucla.edu/Atlases). The analysis is fully
automated by use of a MATLAB batch script and requires about
12 minutes per MRI scan on an Xeon 5620 2.4-GHz PC (Intel,
Santa Clara, California), with 2 quad cores and MATLAB
multithreaded computation-enabled. In short, each T1-weighted
volume dataset was normalized to the standard brain of the
Montreal Neurological Institute (MNI) included in the SPM5
distribution and segmented into different brain compartments, i.e.,
grey matter (GM), white matter (WM), and cerebrospinal fluid.
This was done by using the ‘‘unified segmentation’’ tool of SPM5
with its default settings. The segmentation resulted in ‘‘modulated’’
and ‘‘unmodulated’’ images for the different tissue compartments.
Modulation compensates for dilatation or shrinkage during spatial
normalization and has the effect of preserving the total amount of
signal from the respective tissue class in the normalized partitions
[21]. To determine the volume of a specific brain structure of
interest the corresponding binary mask derived from the LPBA40
atlas was multiplied with the modulated image of the desired tissue
class. The values of all voxels in the resulting image were summed
up and divided by 1,000 to get the volume of the investigated
structure in milliliter units. Because of modulation of the tissue
Table 1. Demographics, Cognitive & Behavioural Tests.
bvFTD AD CON
ANOVA (Main
Effect of Group) bvFTD vs CON AD vs CON bvFTD vs AD
N 15 14 10
Gender (M/F) 11/4 10/4 5/5 n.s. (chi-squared
test)
Age 61.6 (6.6) 63.9 (7.4) 65.5 (6.2) n.s.
Education 11.9 (2.2) 12.8 (3.5) 13.2 (1.8) n.s.
MMSE [30] 25.9 (2.7) 25.3 (2.8) 29.0 (1.2) * * * n.s.
FRS logit score1 0.1 (1.3) 1.5 (1.2) - *
ACE-R [100]2 79.9 (7.5) 74.9 (10.4) 93.6 (4.7) * * * n.s.
CBI-R [180]3 59.3 (25.2) 35.7 (22.5) 4.6 (2.6) * * * *
n.s. = not significant; * = p0.05.
Data available from 1 6 bvFTD and 11 AD, 2 10 bvFTD, 14 AD, and 10 controls, 3 10 bvFTD, 10 AD, and 9 controls. Maximum scores for tests given in brackets. Per group
mean and S.D. (in parentheses).
doi:10.1371/journal.pone.0090814.t001
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images, the effect of normalisation (i.e., extension or shrinkage of
the investigated structure) was compensated for so that the
computed volume represented the volume of the original structure
in native space. Target structures (31 in total, see Table 2) were
chosen a priori for analyses of group differences in volume and
volume change over time. As the frontal and temporal lobes
typically show atrophy in bvFTD, we included as regions of
interest all structures of the LPBA40 atlas that belong to the frontal
and the temporal lobes. Additionally, we took into account recent
studies that described atrophy of the caudate and the insula in
bvFTD [10]. For bilateral structures, the volumes of left and right
were summed up. It has to be noted that the structure labelled as
‘hippocampus’ in the LPBA40 atlas apparently comprises hippo-
campus and amygdala. Each dataset was processed independently
from other datasets with the same, fully automated protocol,
regardless of representing a baseline or follow-up dataset.
Processing of follow-up scans did not require coregistration to
baseline scans.
Statistical analysis
Data were analyzed using SPSS19.0 (SPSS Inc., Chicago, Ill.,
USA). Parametric demographic (age, education), neuropsycholog-
ical (general cognitive tests), disease severity (FRS) and behavioural
(CBI) data were compared across the three groups (bvFTD, AD
and controls) via one-way ANOVAs. A chi-squared test was used
to check for significant differences in gender across all groups.
Results were regarded significant if p,0.05. Based on volumetric
measures, for each of the target structures we calculated:
1. Individual volume at clinic presentation (in ml)
Volumes have been divided by individual intracranial volume
(ICV) and multiplied by average ICV of controls, resulting in
measures of normalised individual volume.
2. Annualised volume change (in %)
In order to take into account multiple measurements, individual
change was approximated by a linear regression (with intercept) of
volumes over time, with beta or slope representing change per year
in ml. Change per year (in ml) was divided by volume at first
presentation, resulting in annualised volume change (in %).
For group comparison statistics two separate sets of ANOVAs
with fixed factor ’group’ and post-hoc Bonferroni tests have been
performed on (1) the independent variables ’volumes at clinic
presentation’, and (2) the independent variables ’annualised
volume change’ of all target structures (see Table 2). Results of
the univariate volumetric analyses were regarded significant if
p,0.05, corrected for multiple comparisons (variables). The
analyses were done using the false discovery rate (FDR) in
multiple testing under the assumption of mutual dependency of the
analysed structures. Univariate tests were followed by correction of
the original p-values according to the method of Benjamini and
Hochberg [22] using the MATLAB script available at [www.
mathworks.com/matlabcentral/fileexchange/27418-benjamini-
hochbergyekutieli-procedure-for-controlling-false-discovery-rate].
This method controls for the expected proportion of false
positive findings and it is less strict than Bonferroni correction.
Results of the post-hoc tests were regarded significant if they
survived an additional Bonferroni correction for multiple
pairwise group comparisons.
The variables which showed a significant difference between
bvFTD and AD in the former analyses were subjected to a binary
logistic regression to determine the best predictor of diagnosis
(bvFTD vs. AD).
Results
Demographics and global cognitive functioning
Demographics and general cognitive scores can be seen in
Table 1. Participant groups did not differ in terms of age,
education, or gender. However, the patient groups differed
significantly in disease severity (Total FRS Corrected: p,0.05)
with bvFTD patients being more impaired. For the cognitive
screening tests (ACE-R and MMSE), both patient groups were
significantly impaired in comparison to controls but did not differ
from each other. Similarly, on the behavioural scores (CBI),
bvFTD and AD patients showed significantly more behavioural
disturbances than age-matched controls, and bvFTD displayed
more severe impairment than AD patients (see Table 1).
Table 2. Anatomical Structures Selected for Volumetric Analyses, based on the LPBA40 atlas.
FLGM — Frontal Lobe FLWM — Frontal Lobe
SFGGM — Superior Frontal Gyrus SFGWM — Superior Frontal Gyrus
MFGGM — Middle Frontal Gyrus MFGWM — Middle Frontal Gyrus
IFGGM — Inferior Frontal Gyrus IFGWM — Inferior Frontal Gyrus
PreGGM — Precentral Gyrus PreGWM — Precentral Gyrus
MOFGGM — Middle Orbitofrontal Gyrus MOFGWM — Middle Orbitofrontal Gyrus
LOFGGM — Lateral Orbitofrontal Gyrus LOFGWM — Lateral Orbitofrontal Gyrus
Gyrus RectusGM Gyrus RectusWM
Grey Matter TLGM — Temporal Lobe White Matter TLWM — Temporal Lobe
STGGM — Superior Temporal Gyrus STGWM — Superior Temporal Gyrus
MTGGM — Middle Temporal Gyrus MTGWM — Middle Temporal Gyrus
ITGGM — Inferior Temporal Gyrus ITGWM — Inferior Temporal Gyrus
PHGGM — Parahippocampal Gyrus PHGWM — Parahippocampal Gyrus
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Brain volumes at clinic presentation
The univariate analyses revealed significant main effects of
factor group for most grey matter volumes and some of the white
matter volumes (see Table 3). Post-hoc Bonferroni tests revealed
that the bvFTD group had significantly smaller volumes of all grey
and white matter structures than the control group. The AD
group, compared to controls, had reduced volumes of all grey
matter structures, except for the middle frontal gyrus (MFGGM),
middle orbitofrontal gyrus (MOFGGM), precentral gyrus (PreGGM)
and the caudate. In contrast, for the white matter volumes only the
middle temporal gyrus (MTGWM) was significantly reduced in AD
compared to controls. bvFTD patients showed smaller volumes of
the caudate and gyrus rectusGM than AD (Table 3; Figure 1). At
group level, AD patients did not have smaller volumes of any of
the target structures than bvFTD patients.
Annualised brain volumetric changes
The univariate analyses revealed a significant group effect for
annualised change of several white matter areas (MTGWM,
TLWM, ITGWM, FLWM, SFGWM, PreGWM, IFGWM, STGWM,
MFGWM, MOFGWM, FGWM, PHGWM), and additional grey
matter changes in the lateral orbitofrontal gyrus (LOFGGM), insula
and the hippocampus & amydala (Table 4). Post-hoc tests revealed
that the bvFTD group had significantly larger atrophy rates of
each of these structures than the group of control participants,
except for white matter in the fusiform gyrus (FGWM). AD
patients, compared to controls, had larger atrophy rates of
temporal lobe (TLWM) and middle temporal gyrus white matter
(MTGWM). The bvFTD patients had larger atrophy rates than AD
in the lateral orbitofrontal gyrus (LOFGGM) (Figure 2).
The measures which showed a significant difference between
bvFTD and AD in the former analyses (caudate and gyrus
rectusGM volumes at clinic presentation, and LOFGGM atrophy
rate) were subjected to a post-hoc binary logistic regression to
determine the best predictor of diagnosis (bvFTD vs. AD). The
forward stepwise logistic regression revealed that caudate volume
at clinic presentation alone predicted 23/29 (79%) cases correctly
(p,0.05; Nagelkerke’s R2 = 0.40). When the gyrus rectusGM was
included in addition to caudate volume, the prediction improved
to 24/29 (83%) (Nagelkerke’s R2 = 0.57; p(Caudate) ,0.05;
Table 3. Anatomical structures that showed significant group differences of volumes at clinic presentation (FDR-corrected p0.05).
Per group mean and S.D. (in ml), univariate between-subjects effects, and pairwise post-hoc Bonferroni test results.
Dependent Variable bvFTD AD CON F(2,36) bvFTD vs CON AD vs CON bvFTD vs AD
Grey Matter
Frontal Lobe
SFGGM 44.75 (4.61) 48.8 (4.99) 56.64 (4.52) 19.07 * * n.s.
LOFGGM 4.38 (0.78) 4.97 (0.34) 5.77 (0.5) 17.2 * * n.s.
FLGM 136.42 (13.55) 148.76 (14.05) 168.2 (13.67) 16.01 * * n.s.
Gyrus RectusGM 3.05 (0.47) 3.49 (0.35) 3.97 (0.37) 15.79 * * *
IFGGM 18.37 (2.33) 20.35 (2.38) 23.32 (2.01) 14.25 * * n.s.
MOFGGM 9.6 (1.22) 10.64 (1.14) 11.59 (0.75) 10.17 * n.s. n.s.
PreGGM 19.74 (1.97) 20.93 (2.65) 23.65 (2.58) 8.19 * n.s. n.s.
MFGGM 36.52 (5.01) 39.58 (4.63) 43.24 (4) 6.32 * n.s. n.s.
Temporal Lobe
TLGM 108.26 (5.81) 112.77 (12.12) 129.98 (9.88) 16.48 * * n.s.
STGGM 27.04 (1.57) 28.97 (4.1) 34.26 (3.54) 15.83 * * n.s.
ITGGM 23.22 (1.9) 24.21 (2.82) 27.52 (1.6) 11.83 * * n.s.
MTGGM 23.7 (1.82) 24.79 (3.52) 28.87 (2.5) 11.52 * * n.s.
Hippocampus & Amygdala 8.85 (0.91) 9.12 (1.83) 10.93 (1.2) 7.55 * * n.s.
PHGGM 9.7 (0.72) 9.92 (0.91) 11.0 (0.98) 7.41 * * n.s.
FGGM 15.75 (1.12) 15.76 (1.36) 17.39 (1.46) 5.92 * * n.s.
Caudate 6.37 (0.91) 7.42 (0.76) 8.29 (0.75) 16.97 * n.s. *
Insula 11.82 (0.83) 13.06 (1.61) 14.89 (1.5) 16.04 * * n.s.
White Matter
Frontal Lobe
IFGWM 13.57 (1.9) 14.35 (2.18) 16.52 (1.93) 6.62 * n.s. n.s.
LOFGWM 1.36 (0.4) 1.58 (0.38) 1.84 (0.27) 5.43 * n.s. n.s.
MOFGWM 4.32 (0.98) 4.8 (0.92) 5.41 (0.52) 4.84 * n.s. n.s.
MFGWM 41.48 (5.26) 45.47 (6.35) 48.01 (3.69) 4.76 * n.s. n.s.
Temporal Lobe
MTGWM 20.98 (2.18) 22.23 (3.13) 24.53 (1.98) 5.98 * * n.s.
n.s. = not significant; * = p0.05, corrected for multiple comparisons
doi:10.1371/journal.pone.0090814.t003
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p(gyrus rectusGM) = 0.062). Atrophy rate of the LOFGGM did not
significantly contribute to the prediction.
Subgroup analyses contrasting data from two scanning
sites
In order to test for systematic differences between volumetric
data acquired at the two different scanning sites, confirmatory T-
tests were applied (p = 0.05). No significant differences were
observed between bvFTD patients from Sydney and bvFTD
patients from Freiburg regarding caudate volume, gyrus rectusGM
volume, or volume change of LOFGGM. Furthermore, each of the
two bvFTD subgroups showed a significant difference compared
to CON concerning caudate volume, gyrus rectusGM volume, and
volume change of LOFGGM. Similarly, each of the two bvFTD
subgroups showed a significant difference compared to AD
regarding caudate volume, gyrus rectusGM volume, and volume
change of LOFGGM, with the exception of the comparison of
gyrus rectusGM volume between bvFTD (Freiburg) and AD, which
failed to reach significance.
Discussion
This study reports annual grey and white matter atrophy
changes in bvFTD and AD. Our findings indicate that white
matter changes are of particular importance when considering
longitudinal neuroimaging changes in these neurodegenerative
conditions.
Cross-sectional findings
Atrophy of frontal, insular and temporal lobe structures was
observed in both bvFTD and AD at clinic presentation, in line
with previous reports in bvFTD [10,12,23–25] and AD [26]. The
largest inter-group difference was observed in the grey matter
volumes of the superior frontal gyrus (SFGGM) being smaller in
both patient groups than controls. The latter region is commonly
associated with executive functions such as planning and
execution, is often reported to be atrophic in bvFTD
[24,25,27,28], and to a lesser extent in AD [26,29]. The bvFTD
group also showed marked caudate atrophy compared to controls
[27,30] and AD [31]. Caudate is, therefore, a potentially
important imaging biomarker for bvFTD and is in keeping with
its role in response inhibition [32], probabilistic learning [33] and
stereotypical behaviour [34], the latter a hallmark feature of
bvFTD. Atrophy of the ventromedial prefrontal cortex is
recognised to be one of the earliest features of bvFTD [11]. Our
findings of greater medial orbitofrontal cortex atrophy (gyrus
rectus) in bvFTD than AD is, therefore, in line with previous
reports [13,23,27]. Importantly, this region has been associated
with disinhibition which is more common in bvFTD than in AD
[4,35]. Interestingly, none of the underlying white matter volumes
in those regions distinguished between bvFTD and AD at
presentation.
Longitudinal findings
Both groups’ annual progression rates were highest in temporal
white matter (temporal lobe, middle temporal gyrus, inferior
temporal gyrus). In addition, the bvFTD group showed significant
annual changes in grey matter regions, with particularly the lateral
orbitofrontal cortex and insula being affected. Annual volume
decrease in the group of healthy elderly controls was ,1% overall
which is commensurate with prior estimates [36,37]. By contrast,
the annual decrease was considerably elevated in AD (2.5%
averaged over participants and structures) and in bvFTD (3.6%
averaged over participants and structures) in line with previous
reports of greater atrophy rates in FTD compared to AD [38–40].
Although the caudate displayed marked atrophy at clinic
presentation in bvFTD, there was no significantly elevated atrophy
rate over a 12 months period. By contrast, the LOFGGM volume
continued to decline at a high rate (grey matter volume decline of
about 6% in bvFTD vs. 1% in controls). These findings highlight
the variability of progression slopes between brain regions, which
can be potentially used for future neuroimaging disease stageing. It
is likely that atrophy in gyrus rectus and caudate, which are known
to be affected early in bvFTD [11,41], might have already
plateaued by the time patients present with little further decline
over the next 12 months. Of note was the finding that white matter
atrophy progression exceeds grey matter degeneration in both
diseases but particularly bvFTD. The fact that bvFTD patients
show greater WM degeneration at presentation has been reported
before [11,27]. We extend these findings by showing for the first
time that bvFTD patients had significantly greater changes over
time (see Table 4).
Clinical implications
The results highlight the fact that MRI volumetry may assist in
the differential diagnosis of bvFTD and AD with loss of volume of
Figure 1. Volumes at clinic presentation (ml; Mean +/– 1 S.D.) of caudate and gyrus rectus grey matter. Brackets indicate significant
group differences. Red dots indicate data from Freiburg. CON = control participants.
doi:10.1371/journal.pone.0090814.g001
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the caudate supporting a clinical diagnosis of bvFTD. Identifica-
tion of subcortical changes might therefore be more predictive
than cortical changes, which often have been shown to overlap
between the diseases. The observed longitudinal changes in our
study may also be important for disease stageing of bvFTD and
AD, in conjunction with other disease severity measures such as
the FRS [18] or CDR-FTLD [42]. Finally, the longitudinal
changes will allow tracking of disease progress tracking, which is
critical to measuring the efficacy of disease modifying therapies. In
addition to tracking overall volume loss it may be germane to
consider particular structures such as temporal white matter or
grey matter of the lateral orbitofrontal gyrus.
Limitations & future directions
Despite these promising findings, our study had several
limitations. We pre-selected regions, based on current knowledge
of bvFTD, which potentially excluded other regions that might be
of interest, e.g., parietal regions. Data from two different scanning
sites have been pooled in the analyses. However, for each
individual the scanning site and protocol have consistently been
held constant. Moreover, subgroup analyses did not detect any
systematic difference between data from the two sites, and
subgroups essentially replicated the findings obtained from pooled
data. Volumetric measures of each structure were combined over
the left and right hemispheres in this study, which excludes
analyses of atrophy asymmetries. The investigation of atrophy in
degenerative diseases with a well-known lateralisation, like
primary progressive aphasia, might benefit from separate assess-
ment of left and right hemisphere structures. There was also no
pathological confirmation of our cases, which leaves the possibility
that a percentage of cases had a mis-match of clinical diagnosis
and underlying pathology. Finally, surprisingly high atrophy
Figure 2. Annualised volume change (%; mean +/– 1 S.D.) of
LOFG grey matter. Brackets indicate significant group differences.
Red dots indicate data from Freiburg. CON = control participants.
doi:10.1371/journal.pone.0090814.g002
Table 4. Anatomical structures that showed significant group differences of annualised volume change (FDR-corrected p0.05). Per
group mean and S.D. (in %), univariate between-subjects effects, and pairwise post-hoc Bonferroni test results.
Dependent Variable bvFTD AD CON F(2,36) bvFTD vs CON AD vs CON bvFTD vs AD
Grey Matter
Frontal Lobe
LOFGGM –5.57 (4.5) –2.1 (1.77) –0.99 (1.65) 7.74 * n.s. *
Temporal Lobe
Hippocampus & Amygdala –3.61 (3.24) –3.09 (1.62) –0.95 (0.78) 4.37 * n.s. n.s.
Insula –3.59 (2.85) –2.37 (1.25) –0.73 (0.88) 6.27 * n.s. n.s.
White Matter
Frontal Lobe
FLWM –3.7 (2.57) –2.35 (1.21) –0.7 (1.4) 7.58 * n.s. n.s.
SFGWM –3.84 (2.97) –2.56 (1.35) –0.74 (1.49) 6.20 * n.s. n.s.
PreGWM –3.24 (3.06) –1.84 (2.63) 0.75 (2.82) 5.88 * n.s. n.s.
IFGWM –4.35 (3.28) –3.05 (1.55) –1.26 (1.05) 5.37 * n.s. n.s.
MFGWM –3.29 (2.7) –2.02 (1.08) –0.91 (1.02) 4.98 * n.s. n.s.
MOFGWM –5.46 (2.72) –3.46 (3.46) –2.04 (1.46) 4.75 * n.s. n.s.
Temporal Lobe
MTGWM –2.64 (1.24) –2.08 (0.97) –0.76 (0.47) 10.83 * * n.s.
TLWM –3.75 (2.03) –2.85 (1.25) –0.88 (0.86) 10.65 * * n.s.
ITGWM –5.3 (3.29) –3.87 (2.25) –0.99 (1.3) 8.65 * n.s. n.s.
STGWM –3.9 (2.91) –3.43 (2.87) –0.63 (1.72) 5.04 * n.s. n.s.
FGWM –3.56 (3.26) –1.77 (1.3) –1.12 (0.77) 4.25 n.s. n.s. n.s.
PHGWM –6.81 (6.79) –5.59 (2.34) –1.55 (1.35) 4.24 * n.s. n.s.
n.s. = not significant; * = p0.05, corrected for multiple comparisons.
doi:10.1371/journal.pone.0090814.t004
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progression rates were observed in the white matter of several
brain structures, which suggests that longitudinal WM imaging
with diffusion tensor imaging might provide additional insight into
ongoing disease processes in bvFTD and AD.
Conclusion
In summary, we show that automated MRI volumetry may help
to discriminate dementia patients from controls and differentiate
between dementia subtypes. While grey matter atrophy is already
present at clinic presentation in bvFTD and AD, white matter
atrophy follows with the steepest decline.
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